Yaxin Zhang, Anyuyang Fan, Juan Du, Xuemei Shi, Shiyu Yang, Na Gao, Lili Pan, Taotao Li
{"title":"高安动脉炎患者抑郁的风险因素和预后。","authors":"Yaxin Zhang, Anyuyang Fan, Juan Du, Xuemei Shi, Shiyu Yang, Na Gao, Lili Pan, Taotao Li","doi":"10.1177/1759720X241296414","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Takayasu arteritis (TA) is associated with an increased risk of developing complicated comorbidities, which can bring both psychological and physical burdens to the patients.</p><p><strong>Objective: </strong>TA is found to carry a high risk of developing depression. This research aimed to investigate the risk factors and prognosis of depression in TA patients.</p><p><strong>Design: </strong>A longitudinal observation cohort was conducted on TA patients with or without depression to explore the clinical characteristics.</p><p><strong>Methods: </strong>In this cohort study, 90 TA patients were split into two groups with or without depression. Depression was evaluated by the Hospital Anxiety and Depression Scale (HADS) in TA patients. TA patients with depression were followed up for at least 3 months. We used multivariate logistic regression analysis to find the risk factors and Kaplan-Meier curve analysis to determine the prognosis.</p><p><strong>Results: </strong>We concluded 90 TA patients in this research, 29 of whom were in depression. Indian Takayasu's Arteritis Activity Score (ITAS2010) ⩾2 (odds ratio (OR) (95% confidence interval, CI) 26.664 (2.004-354.741), <i>p</i> = 0.013), interleukin-6 (IL-6) (OR (95% CI) 1.070 (1.022-1.121), <i>p</i> = 0.004), prednisone equivalents (OR (95% CI) 1.101 (1.030-1.177), <i>p</i> = 0.005), and carotidynia (OR (95% CI) 5.829 (1.142-29.751), <i>p</i> = 0.034) have been shown independent risk factors for depression in TA patients. We also identified the association between disease remission with the improvement of HADS-D score (Log-rank <i>p</i> = 0.005, hazard ratio (HR) 0.25) and depression (Log-rank <i>p</i> = 0.043, HR 0.28).</p><p><strong>Conclusion: </strong>Aggressive treatment to achieve remission can promote improvement of depression in patients with TA. Screening for depression should also be performed in patients with elevated disease activity, IL-6, glucocorticoid use, and carotidynia.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"16 ","pages":"1759720X241296414"},"PeriodicalIF":3.4000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11544677/pdf/","citationCount":"0","resultStr":"{\"title\":\"Risk factors and prognosis of depression in Takayasu arteritis patients.\",\"authors\":\"Yaxin Zhang, Anyuyang Fan, Juan Du, Xuemei Shi, Shiyu Yang, Na Gao, Lili Pan, Taotao Li\",\"doi\":\"10.1177/1759720X241296414\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Takayasu arteritis (TA) is associated with an increased risk of developing complicated comorbidities, which can bring both psychological and physical burdens to the patients.</p><p><strong>Objective: </strong>TA is found to carry a high risk of developing depression. This research aimed to investigate the risk factors and prognosis of depression in TA patients.</p><p><strong>Design: </strong>A longitudinal observation cohort was conducted on TA patients with or without depression to explore the clinical characteristics.</p><p><strong>Methods: </strong>In this cohort study, 90 TA patients were split into two groups with or without depression. Depression was evaluated by the Hospital Anxiety and Depression Scale (HADS) in TA patients. TA patients with depression were followed up for at least 3 months. We used multivariate logistic regression analysis to find the risk factors and Kaplan-Meier curve analysis to determine the prognosis.</p><p><strong>Results: </strong>We concluded 90 TA patients in this research, 29 of whom were in depression. Indian Takayasu's Arteritis Activity Score (ITAS2010) ⩾2 (odds ratio (OR) (95% confidence interval, CI) 26.664 (2.004-354.741), <i>p</i> = 0.013), interleukin-6 (IL-6) (OR (95% CI) 1.070 (1.022-1.121), <i>p</i> = 0.004), prednisone equivalents (OR (95% CI) 1.101 (1.030-1.177), <i>p</i> = 0.005), and carotidynia (OR (95% CI) 5.829 (1.142-29.751), <i>p</i> = 0.034) have been shown independent risk factors for depression in TA patients. We also identified the association between disease remission with the improvement of HADS-D score (Log-rank <i>p</i> = 0.005, hazard ratio (HR) 0.25) and depression (Log-rank <i>p</i> = 0.043, HR 0.28).</p><p><strong>Conclusion: </strong>Aggressive treatment to achieve remission can promote improvement of depression in patients with TA. Screening for depression should also be performed in patients with elevated disease activity, IL-6, glucocorticoid use, and carotidynia.</p>\",\"PeriodicalId\":23056,\"journal\":{\"name\":\"Therapeutic Advances in Musculoskeletal Disease\",\"volume\":\"16 \",\"pages\":\"1759720X241296414\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-11-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11544677/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Musculoskeletal Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/1759720X241296414\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Musculoskeletal Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1759720X241296414","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:高安动脉炎(TA)与并发症风险增加有关,并发症会给患者带来心理和生理负担:目的:研究发现,高安动脉炎患者罹患抑郁症的风险很高。本研究旨在调查 TA 患者抑郁症的风险因素和预后:设计:对患有或未患有抑郁症的TA患者进行纵向队列观察,探讨其临床特征:在这项队列研究中,90名TA患者被分为有抑郁症和无抑郁症两组。通过医院焦虑和抑郁量表(HADS)对TA患者的抑郁情况进行评估。我们对患有抑郁症的 TA 患者进行了至少 3 个月的随访。我们使用多变量逻辑回归分析找出风险因素,并使用卡普兰-梅耶曲线分析确定预后:结果:本研究共收治了 90 名 TA 患者,其中 29 人患有抑郁症。印度高安氏动脉炎活动评分(ITAS2010)⩾2(几率比(OR)(95% 置信区间,CI)26.664(2.004-354.741),P = 0.013)、白细胞介素-6(IL-6)(OR(95% CI)1.070(1.022-1.121),P = 0.004)、泼尼松当量(OR(95% CI)1.101(1.030-1.177),p = 0.005)和颈动脉炔诺酮(OR(95% CI)5.829(1.142-29.751),p = 0.034)已被证明是 TA 患者抑郁的独立危险因素。我们还发现,疾病缓解与 HADS-D 评分改善(Log-rank p = 0.005,危险比 (HR) 0.25)和抑郁(Log-rank p = 0.043,HR 0.28)之间存在关联:结论:积极治疗以达到缓解,可促进TA患者抑郁状况的改善。对于疾病活动度升高、IL-6升高、使用糖皮质激素和颈动脉综合征的患者,也应进行抑郁症筛查。
Risk factors and prognosis of depression in Takayasu arteritis patients.
Background: Takayasu arteritis (TA) is associated with an increased risk of developing complicated comorbidities, which can bring both psychological and physical burdens to the patients.
Objective: TA is found to carry a high risk of developing depression. This research aimed to investigate the risk factors and prognosis of depression in TA patients.
Design: A longitudinal observation cohort was conducted on TA patients with or without depression to explore the clinical characteristics.
Methods: In this cohort study, 90 TA patients were split into two groups with or without depression. Depression was evaluated by the Hospital Anxiety and Depression Scale (HADS) in TA patients. TA patients with depression were followed up for at least 3 months. We used multivariate logistic regression analysis to find the risk factors and Kaplan-Meier curve analysis to determine the prognosis.
Results: We concluded 90 TA patients in this research, 29 of whom were in depression. Indian Takayasu's Arteritis Activity Score (ITAS2010) ⩾2 (odds ratio (OR) (95% confidence interval, CI) 26.664 (2.004-354.741), p = 0.013), interleukin-6 (IL-6) (OR (95% CI) 1.070 (1.022-1.121), p = 0.004), prednisone equivalents (OR (95% CI) 1.101 (1.030-1.177), p = 0.005), and carotidynia (OR (95% CI) 5.829 (1.142-29.751), p = 0.034) have been shown independent risk factors for depression in TA patients. We also identified the association between disease remission with the improvement of HADS-D score (Log-rank p = 0.005, hazard ratio (HR) 0.25) and depression (Log-rank p = 0.043, HR 0.28).
Conclusion: Aggressive treatment to achieve remission can promote improvement of depression in patients with TA. Screening for depression should also be performed in patients with elevated disease activity, IL-6, glucocorticoid use, and carotidynia.
期刊介绍:
Therapeutic Advances in Musculoskeletal Disease delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of musculoskeletal disease.